Vertex Pharmaceuticals and Parion Sciences have teamed up to develop new drugs for treatment of cystic fibrosis (CF) and other pulmonary diseases. The companies have initiated a collaboration worth up to $1.17 billion, under which Vertex and Parion will work together to develop investigational epithelial sodium channel (ENaC) inhibitors for …